Most of the presentations at SABCS focus on the latest clinical and basic research results relating to breast cancer. By contrast, educational sessions are designed to inform and update those interested in a review on a particular topic. Although these sessions may include new specific research findings, their primary intent is to offer summaries of existing knowledge, and to provide background for some of the active areas which will be discussed in the rest of the meeting.
Digital Health and PROs in Breast Cancer Research and Care
Moderator: Ann H. Partridge, MD, MPH
Dana Farber Institute
Boston, MA
What are PROs and evidence for benefit?
Shoshana Rosenberg, ScD, MPH
Weill Cornell Medicine
New York, NY
How to incorporate PROs into clinical care
Oluwadamilola
“Lola” Fayanju, MD, MA, MPHS, FACS
Perelman School
of Medicine at the University of Pennsylvania
Philadelphia, PA
Where are we going with digital interventions and PROs
Ines Vaz Luis, PhD
Gustave Roussy
Villejuif, France
Patient Advocate Perspective
Patty Spears, BS
University of North Carolina at Chapel Hill
Chapel Hill, NC
Management of Hereditary Risk: Moderate-Risk Genes and New Approaches
Moderator: Seema A. Khan, MD
Northwestern University
Chicago, IL
Cancer risks in patients with high penetrance gene mutations
Payal D. Shah, MD
Penn Medicine
Philadelphia, PA
Screening for high-risk patients: Does everyone need annual MRI with mammogram?
Madeleine M.A. Tilanus-Linthorst, MD, PhD
Erasmus University Medical Center
Rotterdam, Netherlands
Hormonal exposure and risk in BRCA1/2 carriers
Joanne Kotsopoulos, MSc, PhD
University of Toronto
Toronto, Canada
Antibody Drug Conjugates: Future Directions and Opportunities
Moderator: Ian E. Krop, MD, PhD
Dana-Farber Cancer Institute
Boston, MA
Bioengineering and mechanism of action of ADC
Puja Sapra, PhD
AstraZeneca
New York, NY
ADCs in breast oncology: Present and future
Shanu Modi, MD
Memorial Sloan Kettering Cancer Center
New York, NY
Mechanisms of resistance
Leif Ellison, MD, PhD
Massachusetts General Hospital
Boston, MA
Challenging Types of Breast Cancer
Moderator: Bora Lim, MD
Baylor College of Medicine
Houston, TX
Pathologic aspects
Jorge S. Reis-Filho, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY
Metaplastic
Alexandra Thomas, MD, FACP
Wake Forest Baptist Health
Winston-Salem, NC
Inflammatory
Filipa Lynce, MD
Dana-Farber Cancer Institute
Boston, MA
Lobular/pleomorphic
Sibylle Loibl, MD, PhD
German Breast Group
Neu-isenburg, Germany
Living with Metastatic Breast Cancer
Moderator: Anne Blaes, MD
University of Minnesota
Minneapolis, MN
Early palliative care
Tara L. Kaufmann, MD, MSCE
UT Health Austin
Austin, TX
Support for patients with MBC
Abbey Kaler, MS, APRN, FNP-C
UT MD Anderson Cancer Center
Houston, TX
Financial Toxicity
Fumiko Chino, MD
Memorial Sloan Cancer Center
Boston, MA
Patient Perspective
TBA
Local Therapy - Best Breast Practice
Moderator: TBA
Contralateral mastectomy in patients with germline mutations
Katharine A. Yao, MD
Northshore Medical Group
Evanston, IL
RT: How short can it be
David Krug, Dr Med
Universitätsklinikum Schleswig-Holstein
Kiel, Germany
How to reconcile novel reconstructive techniques with the need to radiate
Christine Solbach, MD, PhD
University Hospital Frankfurt
Frankfurt, Germany
Spatial and Single Cell Characterization of Breast Cancer Progression
Moderator: Christina Curtis, PhD, MSc
Stanford University School of Medicine
Stanford, CA
Single cell profiling
TBA
Multiplex spatial proteomic profiling
David Rimm, MD, PhD
Yale University
New Haven, CT
Imaging mass cytometry of breast cancer
Raza Ali, MD, FRCPC, MSc
Cancer Research UK Cambridge Institute
Cambridge, United Kingdom
Beyond the lab: Clinical implications
Christina Curtis, PhD, MSc
Stanford University School of Medicine
Stanford, CA
Targeting the Tumor Microenvironment for Clinical Impact
Moderator: Diana Cittelly, PhD
University of Colorado Anschutz Medical Campus
Aurora, CO
Influence of bone microenvironment on metastasis
Igor Bado, PhD
Baylor College of Medicine
Houston, TX
The contribution of
the tumor microenvironment to cancer dormancy
J.
Javier Bravo-Cordero, PhD
Icahn
School of Medicine at Mount Sinai
New York, NY
Effects of age on the tumor microenvironment
Sandra S. McAllister, PhD
Harvard Institutes of Medicine
Boston, MA
Can inflammation be targeted?
Angela DeMichele, MD, MSCE
University of Pennsylvania
Philadelphia, PA
What ctDNA Can Tell Us
Moderator: Nicholas Turner, PhD, FRCP
The Royal Marsden Hospital
London, United Kingdom
Which is the best technique
Heather Parsons, MD, MPH
Dana-Farber Cancer Institute
Boston, MA
Can ctDNA substitute tissue testing
Ben O'Leary, MBBS, PhD
The Institute of Cancer Research
London, United Kingdom
Using ctDNA in detecting disease
Minetta C. Liu, MD
Mayo Clinic
Rochester, MN
State of the Art Radiotherapy: Reducing Toxicity and Increasing Options
Moderator: Wendy Woodward, MD, PhD
UT MD Anderson Cancer Center
Houston, TX
Overview of the current state of the art - what patients and oncologists need to know
Rachel Jimenez, MD
Massachusetts General Hospital
Boston, MA
The role of advanced radiation technology in reducing toxicity
TBA
Evidence for ablative radiation in metastatic breast cancer
Chiaojung Jillian Tsai, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY
Predictive Value of Treatment Response and Residual Disease After Neoadjuvant Therapy
Virginia Kaklamani, MD
UT Health San Antonio
San Antonio, TX
ER therapies
Cynthia X. Ma, MD, PhD
Washington University in St. Louis
St. Louis, MO
HER2
Luca Gianni, MD
Fondazione Michelangelo
Milano, Italy
Triple negative
Peter Schmid, MD, PhD
Bart's Cancer Institute
London, United Kingdom
New Agents Targeting HRD in Breast Cancer
Moderator: Erica Stringer-Reasor, MD
University of Alabama at Birmingham
Birmingham, AL
Pol-theta inhibitors in HRD tumors
Alan D. d'Andrea, MD
Dana-Farber Cancer Institute
Boston, MA
Mechanisms of sensitivity and resistance to HRD targeting agents in
breast cancer – PARPi and beyond
Christopher Lord, D.Phil
Institute of Cancer Research
London, United Kingdom
ATR
inhibitors and PARP1 selective PARP inhibitors
Andrew Tutt, MD ChB, MRCP, FRCR, PhD
Institute of Cancer Research
London, United Kingdom
Breast Cancer and Cardiovascular Toxicity: What an Oncologist Needs to Know
Co-Moderator: Carmen Bergom, MD, PhD
Washington University in St. Louis
St. Louis, MO
Co-Moderator: Susan Dent, MD
Duke
Durham, NC
Beyond anthracyclines and trastuzumab: Cardiotoxicity of new novel agents
Susan Dent, MD
Duke
Durham, NC
Radiation therapy and cardiovascular disease in breast cancer
Carmen Bergom, MD, PhD
Washington University in St. Louis
St. Louis, MO
Cardiovascular toxicity and breast cancer: Detection and prevention strategies
TBA
Cardiac problems secondary to chemotherapy
TBA